Clinical Trials Outsourcing Market - Global Outlook & Forecast 2022-2027

Clinical Trials Outsourcing Market - Global Outlook & Forecast 2022-2027

The clinical trials outsourcing market is expected to grow at a CAGR of 6.71%during 2022-2027.

The pharma & biotech companies hire other companies to conduct the clinical trials, as the companies do not have the expertise, time, or infrastructure to carry out the clinical trials. Outsourcing clinical trials delivers advantages such as cost efficiency, minimum timeline, and best result delivery. Most clinical trials are outsourced to contract research organizations and third-party vendors.

Clinical trial outsourcing delivers significant advantages in terms of cost. Clinical drug development trials are vital, requiring higher expenditure and high-class infrastructure and expertise. Due to the complexity of clinical trial processes, sponsors constantly face pressure from regulatory agencies, insurers, and the medical community to reduce costs by increasing the size of development projects, their pipelines' pipeline quality and safety of their products, and their compliance with regulatory requirements.

Most Biopharmaceutical companies spend their higher expenditure on research & development activities and clinical trials. In the end, lower chances of success rate impact the company's growth largely; therefore, outsourcing easily reduces this complexity. Remote trials can reduce around 25% to 30% trials cost due to the services associated with patient travel and the number of staff required for monitoring on the site.

Impact of Covid-19 Pandemic

The Covid-19 pandemic gave an absolute massive shift and forced the clinical trial industries to look for outsourcing. Clinical trial complexity is a significant factor that drives clinical trial outsourcing. Robust pipelines and stringent regulations in clinical trials operate the clinical development services.

Virtual Clinical Trials: The Rising Market

Virtual clinical trials are a rapidly increasing trend in biopharma industries. It is one of the new clinical trial models, a highly underutilized method for conducting clinical trials and clinical research. Virtual clinical trials are cost-effective, time-saving, and easier for participants. Virtual collaboration strategies in clinical trials, using clinical trials software allows businesses to work rapidly and more efficiently, eliminates the need for document sharing to additional office locations, and reduces the burden.

KEY INDUSTRY INSIGHTS

  • Downscaling the companies, managing the cost of the research, and reducing the expenditure has led to raised clinical trial outsourcing by the biopharmaceutical industry. The three significant factors, globalization, digitalization, and personalized medicines, highly impacted the clinical trials industries. These three major factors have positively influenced the clinical trial outsourcing market growth in recent years.
  • Across the world, the rising patient population is one of the major problems for developed countries as their healthcare expenditure is increasing, so there is a demand for advanced treatments which provide value-based solutions to the patients. Biopharmaceutical companies constantly look for new drugs and derived clinical trial activities. Pharma Research and development outsourcing activities are significant in the industry, giving high potential for this market and related activities and triggering the demand for clinical trials outsourcing.
  • AI in clinical trials is a revolutionizing technology primarily adopted among large CROs. In recent years AI application was rapidly explored during the COVID-19 pandemic period accelerating the clinical trials for a faster cure for the pandemic.
  • The Indian biotech industry alone accounts for 2,700 start-ups, and the estimated number will increase to 10,000 by 2024. Globally, more than 2,093,000 pharma start-ups are running in the market; this rise in smaller companies will demand outsourcing clinical trials.
  • Synthetic Data Improving Clinical Development minimizes or replaces the control arm of the clinical trial. It reduces the demand for patient recruitment, saves time and money, and eliminates the ethical issues regarding the placebo.
Usually, the pharma companies do not have access to real-world data. They majorly limit themselves within the clinical trials that they have conducted. This synthetic data, which is from real-world data, will help the companies to understand the real world and help them to find better solutions. Currently, there is an increase in single-arm clinical trials for rare diseases and oncology therapeutic areas. This has made it easy for people to work when comparing treatments. The entry of synthetic and external control arms has changed rapidly and growing significantly by enabling improved access to data, including statistical tool kits from various clinical research fields.

Segmentation by Application
  • Cancer
  • CVDs
  • Infectious Diseases
  • Infectious Diseases
  • Musculoskeletal Diseases
  • Nervous System Disorders
  • Other Diseases
Segmentation by Clinical Trial Phase
  • Phase I
  • Phase II
  • Phase III
  • Phase IV
Segmentation by End-Users
  • Small & Mid-Size Companies
  • Large Size Companies
CLINICAL TRIALS OUTSOURCING MARKET TRENDS
  • Implementing artificial intelligence (AI) in clinical trials is a revolutionizing technology, primarily adopted among large CROs. In recent years AI application was rapidly explored during the COVID-19 pandemic period accelerating the clinical trials for a faster cure for the pandemic. AI (Artificial Intelligence) helps make every clinical trial stage more efficient with design and patient recruitment and retention, followed by clinical trials outsourcing services by contract research organizations. It also allowed the companies to manage the extensive data without any errors and make decisions accordingly.
  • Pharmaceutical and biotech companies are relying on research and development activities to develop new drugs. Rising expenditure on clinical research and development will deliver high market growth opportunities.
  • An excellent opportunity for outsourcing clinical trials lies in rare diseases due to the limited patient population and rising prevalence of rare diseases globally. For outsourcing leaders, patient recruitment and retention are easy with the rising prevalence of rare diseases in low-middle companies. These CROs have an excellent partnership with government bodies and large healthcare providers to recruit patients. Most outsourcing companies are based in low-middle-income countries.
  • The increasing demand for large molecules and personalized medicines such as cell and gene therapies have also helped drive the CRO outsourcing market consistently.
  • An increasing number of small biopharma companies is one of the best clinical trial outsourcing market opportunities. The small and medium-sized biopharma companies account for a higher number of clinical research. Due to lower capital availability, lack of infrastructure, and expertise, small biopharma companies look towards outsourcing clinical trials.
INSIGHTS BY GEOGRAPHY

North America is the leading region in clinical trial outsourcing. But in recent years, clinical trial outsourcing shifting towards the emerging market. Emerging markets such as low-middle-income countries are the best geography for this market due to the high patient population and unaffordable pricing of new treatments or existing treatments in the LMICs.

On the other side, some emerging markets, such as BRICS (Brazil, Russia, India, China, and South Africa), have a better opportunity for clinical trials outsourcing market. These emerging geographies have a high potential for outsourcing trials. High patient pool demography is one of the strong reasons for outsourcing in those countries.

Segmentation by Geography
  • APAC
  • China
  • Japan
  • South Korea
  • Australia
  • India
  • North America
  • US
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Spain
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • UAE
Key Vendors:
  • Charles River Laboratories
  • IQVIA
  • ICON plc
  • Labcorp Drug Development
  • Syneos Health
  • Thermo Fischer Scientific
  • Wuxi AppTec
  • Paraxel
Other Prominent Vendors
  • Advanced Clinical
  • Bioanalytix
  • Curia Global
  • CMED
  • Cromos Pharma
  • Criterium
  • KCR SA.
  • Medpace
  • Medelis
  • Oct Group
  • Protrials Research
  • Prometrika
  • Quality Data Services
  • QPS
  • Sofpromed
  • Veristat
  • Worldwide Clinical Trials
KEY QUESTIONS ANSWERED

1. WHAT IS THE EXPECTED GROWTH OF THE CLINICAL TRIALS OUTSOURCING MARKET IN THE GLOBAL MARKET?

2. WHO ARE THE MAJOR PLAYERS IN THE CLINICAL TRIALS OUTSOURCING MARKET?

3. WHAT IS THE GROWTH RATE OF THE CLINICAL TRIALS OUTSOURCING MARKET?

4. HOW DOES COVID-19 IMPACT THE MARKET GROWTH OF CLINICAL TRIALS OUTSOURCING MARKET SHARE?

5. WHAT ARE THE FACTORS DRIVING THE CLINICAL TRIALS OUTSOURCING MARKET GROWTH?


1 RESEARCH METHODOLOGY
2 RESEARCH OBJECTIVES
3 RESEARCH PROCESS
4 SCOPE & COVERAGE
4.1 MARKET DEFINITION
4.1.1 INCLUSIONS
4.1.2 EXCLUSIONS
4.1.3 MARKET ESTIMATION CAVEATS
4.2 BASE YEAR
4.3 SCOPE OF THE STUDY
4.3.1 MARKET SEGMENTATION BY CLINICAL TRIAL PHASE
4.3.2 MARKET SEGMENTATION BY APPLICATION
4.3.3 MARKET SEGMENTATION BY END USER
4.3.4 MARKET SEGMENTATION BY GEOGRAPHY
5 REPORT ASSUMPTIONS & CAVEATS
5.1 KEY CAVEATS
5.2 CURRENCY CONVERSION
5.3 MARKET DERIVATION
6 MARKET AT A GLANCE
7 INTRODUCTION
7.1 OVERVIEW
8 PREMIUM INSIGHTS
8.1 OVERVIEW
8.1.1 TRENDS IN CLINICAL TRIALS OUTSOURCING
9 MARKET OPPORTUNITIES & TRENDS
9.1 RISING DEMAND FOR PATIENT-CENTRIC & DECENTRALIZED CLINICAL TRIALS
9.2 REVOLUTIONIZING EFFECTS OF AI ON CLINICAL TRIALS
9.3 ENTRY OF START-UPS SPECIALIZING IN DRUG DISCOVERY
9.4 INCREASING ADOPTION OF SYNTHETIC CLINICAL TRIALS
10 MARKET GROWTH ENABLERS
10.1 SURGE IN DRUG DISCOVERY INITIATIVES AND ASSOCIATED EXPENDITURE
10.2 HIGH DEMAND FOR LARGE MOLECULE PRODUCTS & PERSONALIZED MEDICINES
10.3 INITIATIVES TO IMPROVE EFFICIENCY IN CLINICAL TRIALS
10.4 RISE IN STRATEGIC PARTNERSHIPS AND R&D COLLABORATIONS
11 MARKET RESTRAINTS
11.1 GEOGRAPHICAL LOCATIONS AND CRUCIAL REGULATORY ASPECTS FOR CLINICAL TRIALS
11.2 LONG TIMELINES AND LACK OF TRANSPARENCY & SPECIFICITY
11.3 INCREASING COMPLEXITY OF CLINICAL TRIALS
12 MARKET LANDSCAPE
12.1 MARKET OVERVIEW
12.1.1 INSIGHTS BY GEOGRAPHY
12.1.2 INSIGHTS BY CLINICAL TRIALS PHASE
12.1.3 INSIGHTS BY APPLICATION
12.1.4 INSIGHTS BY END USERS
12.2 MARKET SIZE & FORECAST
12.3 FIVE FORCES ANALYSIS
12.3.1 THREAT OF NEW ENTRANTS
12.3.2 BARGAINING POWER OF SUPPLIERS
12.3.3 BARGAINING POWER OF BUYERS
12.3.4 THREAT OF SUBSTITUTES
12.3.5 COMPETITIVE RIVALRY
13 PHASE
13.1 MARKET SNAPSHOT & GROWTH ENGINE
13.1.1 MARKET SIZE & FORECAST
13.2 MARKET OVERVIEW
13.3 PHASE III
13.3.1 MARKET OVERVIEW
13.3.2 MARKET BY GEOGRAPHY
13.4 PHASE II
13.4.1 MARKET OVERVIEW
13.4.2 MARKET SIZE & FORECAST
13.4.3 MARKET BY GEOGRAPHY
13.5 PHASE IV
13.5.1 MARKET OVERVIEW
13.5.2 MARKET SIZE & FORECAST
13.5.3 MARKET BY GEOGRAPHY
13.6 PHASE I
13.6.1 MARKET OVERVIEW
13.6.2 MARKET SIZE & FORECAST
13.6.3 MARKET BY GEOGRAPHY
14 APPLICATION
14.1 MARKET SNAPSHOT & GROWTH ENGINE
14.2 MARKET OVERVIEW
14.3 CANCER
14.3.1 MARKET OVERVIEW
14.3.2 MARKET SIZE & FORECAST
14.3.3 MARKET BY GEOGRAPHY
14.4 CARDIOVASCULAR DISEASES
14.4.1 MARKET OVERVIEW
14.4.2 MARKET SIZE & FORECAST
14.4.3 MARKET BY GEOGRAPHY
14.5 NERVOUS SYSTEM DISORDERS
14.5.1 MARKET OVERVIEW
14.5.2 MARKET SIZE & FORECAST
14.5.3 MARKET BY GEOGRAPHY
14.6 INFECTIOUS DISEASES
14.6.1 MARKET OVERVIEW
14.6.2 MARKET SIZE & FORECAST
14.6.3 MARKET BY GEOGRAPHY
14.7 MUSCULOSKELETAL DISEASES
14.7.1 MARKET OVERVIEW
14.7.2 MARKET SIZE & FORECAST
14.7.3 MARKET BY GEOGRAPHY
14.8 GASTROENTEROLOGY DISEASES
14.8.1 MARKET OVERVIEW
14.8.2 MARKET SIZE & FORECAST
14.8.3 MARKET BY GEOGRAPHY
14.9 OTHERS
14.9.1 MARKET OVERVIEW
14.9.2 MARKET SIZE & FORECAST
14.9.3 MARKET BY GEOGRAPHY
15 END USER
15.1 MARKET SNAPSHOT & GROWTH ENGINE
15.2 MARKET OVERVIEW
15.3 SMALL & MID-SIZE COMPANIES
15.3.1 MARKET OVERVIEW
15.3.2 MARKET SIZE & FORECAST
15.3.3 MARKET BY GEOGRAPHY
15.4 LARGE ENTERPRISES
15.4.1 MARKET OVERVIEW
15.4.2 MARKET SIZE & FORECAST
15.4.3 MARKET BY GEOGRAPHY
16 GEOGRAPHY
16.1 MARKET SNAPSHOT & GROWTH ENGINE
16.2 GEOGRAPHIC OVERVIEW
17 NORTH AMERICA
17.1 MARKET OVERVIEW
17.2 MARKET SIZE & FORECAST
17.3 PHASE
17.3.1 MARKET SIZE & FORECAST
17.4 APPLICATION
17.4.1 MARKET SIZE & FORECAST
17.5 END USER
17.5.1 MARKET SIZE & FORECAST
17.6 KEY COUNTRIES
17.6.1 US: MARKET SIZE & FORECAST
17.6.2 CANADA: MARKET SIZE & FORECAST
18 EUROPE
18.1 MARKET OVERVIEW
18.2 MARKET SIZE & FORECAST
18.3 PHASE
18.3.1 MARKET SIZE & FORECAST
18.4 APPLICATION
18.4.1 MARKET SIZE & FORECAST
18.5 END USER
18.5.1 MARKET SIZE & FORECAST
18.6 KEY COUNTRIES
18.6.1 GERMANY: MARKET SIZE & FORECAST
18.6.2 UK: MARKET SIZE & FORECAST
18.6.3 FRANCE: MARKET SIZE & FORECAST
18.6.4 SPAIN: MARKET SIZE & FORECAST
18.6.5 ITALY: MARKET SIZE & FORECAST
19 APAC
19.1 MARKET OVERVIEW
19.2 MARKET SIZE & FORECAST
19.3 PHASE
19.3.1 MARKET SIZE & FORECAST
19.4 APPLICATION
19.4.1 MARKET SIZE & FORECAST
19.5 END USER
19.5.1 MARKET SIZE & FORECAST
19.6 KEY COUNTRIES
19.6.1 CHINA: MARKET SIZE & FORECAST
19.6.2 JAPAN: MARKET SIZE & FORECAST
19.6.3 INDIA: MARKET SIZE & FORECAST
19.6.4 AUSTRALIA: MARKET SIZE & FORECAST
19.6.5 SOUTH KOREA: MARKET SIZE & FORECAST
20 LATIN AMERICA
20.1 MARKET OVERVIEW
20.2 MARKET SIZE & FORECAST
20.3 PHASE
20.3.1 MARKET SIZE & FORECAST
20.4 APPLICATION
20.4.1 MARKET SIZE & FORECAST
20.5 END USER
20.5.1 MARKET SIZE & FORECAST
20.6 KEY COUNTRIES
20.6.1 BRAZIL: MARKET SIZE & FORECAST
20.6.2 MEXICO: MARKET SIZE & FORECAST
21 MIDDLE EAST & AFRICA
21.1 MARKET OVERVIEW
21.2 MARKET SIZE & FORECAST
21.3 PHASE
21.3.1 MARKET SIZE & FORECAST
21.4 APPLICATION
21.4.1 MARKET SIZE & FORECAST
21.5 END USER
21.5.1 MARKET SIZE & FORECAST
21.6 KEY COUNTRIES
21.6.1 TURKEY: MARKET SIZE & FORECAST
21.6.2 EGYPT: MARKET SIZE & FORECAST
21.6.3 SOUTH AFRICA: MARKET SIZE & FORECAST
21.6.4 SAUDI ARABIA: MARKET SIZE & FORECAST
22 COMPETITIVE LANDSCAPE
22.1 COMPETITION OVERVIEW
22.2 MARKET SHARE ANALYSIS
22.2.1 CHARLES RIVER LABORATORIES
22.2.2 IQVIA
22.2.3 ICON PLC
22.2.4 LABCORP DRUG DEVELOPMENT
22.2.5 SYNEOS HEALTH
22.2.6 THERMO FISCHER SCIENTIFIC
22.2.7 WUXI APPTEC
22.2.8 PARAXEL
23 KEY COMPANY PROFILES
23.1 CHARLES RIVER LABORATORIES
23.1.1 BUSINESS OVERVIEW
23.1.2 PRODUCT OFFERINGS
23.1.3 KEY STRATEGIES
23.1.4 KEY STRENGTHS
23.1.5 KEY OPPORTUNITIES
23.2 IQVIA
23.2.1 BUSINESS OVERVIEW
23.2.2 PRODUCT OFFERINGS
23.2.3 KEY STRATEGIES
23.2.4 KEY STRENGTHS
23.2.5 KEY OPPORTUNITIES
23.3 ICON PLC
23.3.1 BUSINESS OVERVIEW
23.3.2 PRODUCT OFFERINGS
23.3.3 KEY STRATEGIES
23.3.4 KEY STRENGTHS
23.3.5 KEY OPPORTUNITIES
23.4 LABCORP DRUG DEVELOPMENT
23.4.1 BUSINESS OVERVIEW
23.4.2 SERVICE OFFERINGS
23.4.3 KEY STRATEGIES
23.4.4 KEY STRENGTHS
23.4.5 KEY OPPORTUNITIES
23.5 SYNEOS HEALTH
23.5.1 BUSINESS OVERVIEW
23.5.2 SERVICE OFFERINGS
23.5.3 KEY STRATEGIES
23.5.4 KEY STRENGTHS
23.5.5 KEY OPPORTUNITIES
23.6 THERMO FISHER SCIENTIFIC
23.6.1 BUSINESS OVERVIEW
23.6.2 SERVICE OFFERINGS
23.6.3 KEY STRATEGIES
23.6.4 KEY STRENGTHS
23.6.5 KEY OPPORTUNITIES
23.7 WUXI APPTEC
23.7.1 BUSINESS OVERVIEW
23.7.2 SERVICE OFFERINGS
23.7.3 KEY STRATEGIES
23.7.4 KEY STRENGTHS
23.7.5 KEY OPPORTUNITIES
23.8 PARAXEL
23.8.1 BUSINESS OVERVIEW
23.8.2 SERVICE OFFERINGS
23.8.3 KEY STRATEGIES
23.8.4 KEY STRENGTHS
23.8.5 KEY OPPORTUNITIES
24 OTHER PROMINENT VENDORS
24.1 ADVANCED CLINICAL
24.1.1 BUSINESS OVERVIEW
24.1.2 SERVICE OFFERINGS
24.2 BIOANALYTIX
24.2.1 BUSINESS OVERVIEW
24.2.2 SERVICE OFFERINGS
24.3 CURIA GLOBAL
24.3.1 BUSINESS OVERVIEW
24.3.2 SERVICE OFFERINGS
24.4 CMED
24.4.1 BUSINESS OVERVIEW
24.4.2 SERVICE OFFERINGS
24.5 CROMOS PHARMA
24.5.1 BUSINESS OVERVIEW
24.5.2 SERVICE OFFERINGS
24.6 CRITERIUM
24.6.1 BUSINESS OVERVIEW
24.6.2 SERVICE OFFERINGS
24.7 KCR S.A.
24.7.1 BUSINESS OVERVIEW
24.7.2 SERVICE OFFERINGS
24.8 MEDPACE
24.8.1 BUSINESS OVERVIEW
24.8.2 SERVICE OFFERINGS
24.9 MEDELIS
24.9.1 BUSINESS OVERVIEW
24.9.2 SERVICE OFFERINGS
24.10 OCT GROUP
24.10.1 BUSINESS OVERVIEW
24.10.2 SERVICE OFFERINGS
24.11 PROTRIALS RESEARCH
24.11.1 BUSINESS OVERVIEW
24.11.2 SERVICE OFFERINGS
24.12 PROMETRIKA
24.12.1 BUSINESS OVERVIEW
24.12.2 SERVICE OFFERINGS
24.13 QUALITY DATA SERVICES
24.13.1 BUSINESS OVERVIEW
24.13.2 SERVICE OFFERINGS
24.14 QPS
24.14.1 BUSINESS OVERVIEW
24.14.2 SERVICE OFFERINGS
24.15 SOFPROMED
24.15.1 BUSINESS OVERVIEW
24.15.2 SERVICE OFFERINGS
24.16 VERISTAT
24.16.1 BUSINESS OVERVIEW
24.16.2 SERVICE OFFERINGS
24.17 WORLDWIDE CLINICAL TRIALS
24.17.1 BUSINESS OVERVIEW
24.17.2 SERVICE OFFERINGS
25 REPORT SUMMARY
25.1 KEY TAKEAWAYS
25.2 STRATEGIC RECOMMENDATIONS
26 QUANTITATIVE SUMMARY
26.1 MARKET BY GEOGRAPHY
26.2 MARKET BY PHASE
26.3 MARKET BY APPLICATION
26.4 MARKET BY END USER
26.5 MARKET BY PHASE
26.5.1 PHASE III: GEOGRAPHY DISTRIBUTION
26.5.2 PHASE II: GEOGRAPHY DISTRIBUTION
26.5.3 PHASE IV: GEOGRAPHY DISTRIBUTION
26.5.4 PHASE I: GEOGRAPHY DISTRIBUTION
26.6 MARKET BY APPLICATION
26.6.1 CANCER: GEOGRAPHY DISTRIBUTION
26.6.2 CARDIOVASCULAR DISEASES (CVDS): GEOGRAPHY DISTRIBUTION
26.6.3 NERVOUS SYSTEM DISORDERS: GEOGRAPHY DISTRIBUTION
26.6.4 INFECTIOUS DISEASES: GEOGRAPHY DISTRIBUTION
26.6.5 MUSCULOSKELETAL DISEASES: GEOGRAPHY DISTRIBUTION
26.6.6 GASTROENTEROLOGY DISEASES: GEOGRAPHY DISTRIBUTION
26.6.7 OTHER DISEASES: GEOGRAPHY DISTRIBUTION
26.7 MARKET BY END USER
26.7.1 SMALL & MID-SIZE COMPANIES: GEOGRAPHY DISTRIBUTION
26.7.2 LARGE ENTERPRISES: GEOGRAPHY DISTRIBUTION
27 APPENDIX
27.1 ABBREVIATIONS

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings